Board of Directors

OvaScience is a global life sciences company dedicated to improving fertility for women around the world.


Dr. Dipp is a co-founder and Partner of Longwood Fund. Dr. Dipp has co-founded Longwood portfolio companies OvaScience (NASDAQ: OVAS) where she serves as Chairman of the Board and previously served as CEO, Axial Biotherapeutics, where she serves as Chairman of the Board, Alnara Pharmaceuticals (acquired by Eli Lilly), Verastem (NASDAQ: VSTM) and Flex Pharma (NASDAQ: FLKS). Previously, Dr. Dipp was the Senior Vice President and Head of GlaxoSmithKline’s (NYSE: GSK) Centre of Excellence for External Drug Discovery (CEEDD). Prior to leading GSK’s CEEDD, Dr. Dipp was the Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GSK). Before joining Sirtris as a co-founder, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, the Beth Israel Deaconess Medical Center Board of Directors, and the Boston Symphony Orchestra Board of Overseers. In 2015, Dr. Dipp was elected to join the World Economic Forum’s Young Global Leaders and was named to Fortune magazine’s 40 Under 40 list. Dr. Dipp is the women’s health contributor for Arianna Huffington’s Thrive Global.

Dr. Dipp holds a BM, BCh (MD equivalent) from University of Oxford Medical School and a DPhil (PhD equivalent) in Physiology from the University of Oxford. Dr. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford.


Mr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Concert Pharmaceuticals, where he serves as Chairman of the Board of Directors, Sirtris Pharmaceuticals (acquired by GlaxoSmithKline in 2008), and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem, OvaScience, and FlexPharma. Mr. Aldrich also serves as a Director of Longwood portfolio companies Mitobridge, Inc., Colorescience, Inc., and KalVista Pharmaceuticals. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich also serves on the Board of the Massachusetts Eye & Ear Infirmary.

Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.


Jeffrey D. Capello is the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, which was acquired by The Carlyle Group from Johnson & Johnson, with responsibility for global finance and business development. Prior to his role at Ortho-Clinical Diagnostics, he served as Executive Vice President and Chief Financial Officer of Boston Scientific from 2010 to 2013. There he was directly responsible for the worldwide management of Boston Scientific’s Finance Information Systems, Business Development and Corporate Strategy functions. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for Business Development at PerkinElmer, Inc., from 2006 to 2008. Prior to that, he served as PerkinElmer’s Vice President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at Pricewaterhouse Coopers LLP, both in the United States and in the Netherlands. Mr. Capello was a member of the board of directors of Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline) and served on its Audit Committee as both a member and its chair.

Mr. Capello holds a B.S. in Business Administration from the University of Vermont and an M.B.A. from the Harvard Business School. Mr. Capello is also a Certified Public Accountant.


Ms. Fisher brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, where she was responsible for the execution of the company’s restructuring, initial public offering and a $50 million acquisition that transitioned Acorda from a developmental platform to a commercial stage operation. Ms. Fisher has served as a Pharmaceutical Consultant for companies such as Acorda Therapeutics and Roche Diagnostics and specialized in commercialization strategy, resource and outsource planning, pricing strategy and tactics, distribution planning, managed care contracting and forecasting. Previously, she held the role of Vice President, Strategic Healthcare and Commercial Operations at Cephalon, Inc., and Manager, Communications at Immunex. She currently serves as a Board Member of the Neuroscience Nursing Foundation and is a Member of the Women’s Dermatological Society and the Dermatology Foundation Leader’s Society. Additionally, Ms. Fisher co-founded Ann Olsen Endowment, a cancer patient advocacy group, in 1987.


Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe’s tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the health education and life improvement of women and children. Before Project HOPE, Dr. Howe held the Distinguished Chair in Health Policy at The University of Texas Health Science Center at San Antonio; he served as the Center’s chief executive from 1985 through 2000 and is currently the President Emeritus. He is a board member of BB&T Bank, the Chinese Center for Communicable Disease Control and Prevention, the John E. Fogarty International Center at the National Institutes of Health and the Texas Biomedical Research Institute, among others. Among Dr. Howe’s numerous honors and awards are the U.S. Army’s Commander’s Award for Public Service, the Surgeon General’s Exemplary Service Award and the Magnolia Award from the City of Shanghai, China. Dr. Howe is a published author of numerous articles, chapters and abstracts in medical journals, including the New England Journal of Medicine and the Annals of Internal Medicine, among others.

Dr. Howe holds a Bachelor of Arts from Amherst College and an M.D. from Boston University School of Medicine.


Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. Mr. Kozin served as president of the North American practice of L.E.K., a global strategy consulting firm, for 15 years and has been a Senior Advisor to L.E.K. since July 2011. He currently serves as a member of the Board of Directors of UFP Technologies, Inc., DYAX Corp., Endocyte, Inc., and three privately-held companies. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm.

Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania.


Dr. Sexton is the fifteenth President of NYU, serving in the role since 2001. He is a Fellow of the American Academy of Arts and Sciences, a member of the Council on Foreign Relations, and a past member of the Executive Committee of the Association of American Universities. He previously served as the Chairman of the Board of the Federal Reserve Bank of New York and Chair of the Federal Reserve Systems Council of Chairs. He was awarded the TIAA-CREF Hesburgh Award for Leadership Excellence, the Foreign Policy Association Medal, the NASPA President’s Award for advancing the quality of student life at NYU, and was named one of the “Top Ten College Presidents” by TIME magazine. Earlier in his career at NYU, he was the Dean and Benjamin Butler Professor of Law at NYU School of Law. Prior to NYU, Dr. Sexton was Law Clerk to Chief Justice Warren Burger of the United States Supreme Court and to Judges David Bazelon and Harold Leventhal of the United States Court of Appeals. Additionally, Dr. Sexton served as Special Master Supervising Pretrial Proceedings in the Love Canal Litigation. He also served as Professor of Religion and Department Chair at Saint Francis College. Dr. Sexton is a published author of several books, chapters, articles and Supreme Court briefs.

Dr. Sexton holds a B.A. in History from Fordham College, an M.A. in Comparative Religion and a Ph.D. in History of American Religion from Fordham University, and a J.D. from Harvard Law School.